With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.106261-48-7,4-((4-Methylpiperazin-1-yl)methyl)benzoic acid,as a common compound, the synthetic route is as follows.
A mixture of compound 5 (20 mg, 0.05 mmol), 4- (N-methyl-piperazyl)- methyl-benzoic acid (14 mg, 0.06 mmol), 0- (7-azabenzotriazol-1-yl)-N, N, N’, N’- tetramethyl-uronium hexafluorophosphate (23 mg, 0.06 mmol) and diisopropylethylamine (8 mg, 0.06 mmol) in methylene chloride (2 mL) is stirred at room temperature over night. LCMS purification afforded N-(3-{2-[6-(3-dimethylamino-phenylamino)-pyrimidin-4-yl]- phenylamino}-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide (9.2 mg, 30 % yield): ‘H NMR 400 Hz (CDCl3) b 2.51 (s, 3H), 2. 61 (br, 4H), 2.78 (br, 4H), 2.97 (s, 6H), 3.58 (s, 2H), 6.57 (m, 1H), 6.68 (m, 2H), 6.84 (m, 1H), 6.97 (m, 1H), 7.10 (m, 2H), 7.18 (m, 1H), 7.26 (m, 2H), 7.40 (d, J = 8.12 Hz, 2H), 7.46 (d, J = 8.12 Hz, 2H), 7.54 (s, br, 1H), 7.79 (d, J = 8. 14 Hz, 2H), 7.86 (s, 1H), 8.69 (s, 1H); MS m/z (M+H) 613.30., 106261-48-7
Big data shows that 106261-48-7 is playing an increasingly important role.
Reference：
Patent; IRM LLC; WO2005/33086; (2005); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics